**Participant flow diagram**

## Follow-Up

Analysed (n=30)  
 Excluded from analysis (give reasons) (n=0)

## Analysis

Analysed (n=30)  
 Excluded from analysis (give reasons) (n=0)

Lost to follow-up (give reasons) (n=0)

Discontinued intervention (give reasons) (n= 0)

Lost to follow-up (give reasons) (n=0)

Discontinued intervention (give reasons) (n=0)

## Enrollment

Allocated to intervention (n=30)

 Received allocated intervention (n=30)

 Did not receive allocated intervention (give reasons) (n=0)

## Allocation

Allocated to intervention (n=30)

 Received allocated intervention (n=30)

 Did not receive allocated intervention (give reasons) (n=0)

Randomized (n= 60 )

Excluded (n=90 )

  Not meeting inclusion criteria (n=90 )

  Declined to participate (n= )

  Other reasons (n= )

Assessed for eligibility (n=150)

**Baseline Characteristics**

Table 1: Personal characteristics of studied patients.

|  |  |  |  |
| --- | --- | --- | --- |
|  | Group A (Study) (n=30) | Group B (Control) (N=30) | P value |
| Mean Age (Years) | 7.400±1.6836 | 7.167±1.9134 | 0.618 |
| Male/Female | 11/19 | 13/17 | 0.598 |
| Mean Weight (kg) | 27.550±6.6051 | 27.400±8.0026 | 0.937 |
| Height (cm) | 124.667±9.0528 | 121.233±11.46521 | 0.203 |

Data presented as mean ±standard deviation (SD)

p< 0.05 significant/ comparison was done using chi-square test.

**Outcome measures**

**Table 1:** The clinical score for asthma severity during the observation period after treatment in studied patients

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Group A**  **Study**  **(n= 30)** |  | Group B  Controlled  (n= 30) |  | **T** |  | **p-value** |
| **PASS total score 0 min**  **PASS total score 20 min**  **PASS total score 40 min**  **PASS total score 60 min** | **7.433±1.0400**  **5.667±1.4933**  **4.200±1.7889**  **2.567±1.5687** |  | 7.233±.9353  5.967±1.6501  4.533± 1.7760  3.433± 2.1121 |  | **-0.001**  **0.738**  **0.724**  **1.80** |  | **0.996**  **0.463**  **0.472**  **0.0766** |

Data presented as mean ±standard deviation (SD)

**Table 2:** Oxygen saturation assessment during the observation period after treatment in studied patients

**t P value**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **parameters** | **Group A**  **Study**  **(n= 30)** |  | **Group B**  **Controlled**  **(n= 30)** |  |
| SaO2 0 min | **90.400±1.5447** |  | 90.200±1.2149 |  |
| SaO220 min  SaO2 40 min  SaO2 60 min | **94.367±2.4280**  **95.967±1.3257**  **97.467±.8604** |  | 93.067±3.3726  93.833±2.6533  95.033±2.2512 |  |

-0.557 0.579

1.713 0.092

3.939 0.000

5.530 0.000

Data presented as mean ±standard deviation (SD)

**Table 3:** PEFR assessment during the observation period after treatment in studied patients.

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameters** | **Group A**  **Study**  **(n= 30)** | Group B  Controlled  (n= 30) | **t P value** |
| PEFR 0 min | **138.9997±32.3907** | 127.5239±28.1931 | -1.464 0.149 |
|  |  |  |  |
| PEFR20 min  PEFR 40 min  PEFR 60 min | **165.9890±38.8426**  **181.5557±39.6994**  **206.6673±41.3100** | 141.7780±35.57603  146.5567±36.57195  168.1100±41.31688 | 2.518 0.015  3.551 0.001  3.615 0.001 |

Data presented as mean ±standard deviation (SD)

**Adverse Events**

There were no adverse events associated with this study.